论文部分内容阅读
一、引言已经知道大多数恶性肿瘤都可以有其特异抗原或相关抗原,它们能在机体中产生免疫反应,其中细胞介导免疫(CMI)反应在机体抗御恶性肿瘤方面起着主要的作用。所谓细胞免疫是指致敏淋巴细胞再次接触抗原刺激后,效应细胞所产生的特异性免疫作用。测定细胞介导免疫反应的体外试验甚多,如淋巴细胞转化,巨噬细胞移行抑制及细胞毒试验等,这类试验都需要细胞培养的无菌条件和持续较长的时间,并且需要进行复杂的技术操作过程,因而限制了它的推广应用。1972年 Halliday 等首先介绍了一种 CMI 的新的体外检定法,称为白细
I. INTRODUCTION It is known that most malignant tumors can have their specific antigens or related antigens. They can produce immune responses in the body, and cell-mediated immunity (CMI) plays a major role in the body’s resistance to malignant tumors. The so-called cellular immunity refers to the specific immune effect produced by the effector cells after the sensitized lymphocytes are again exposed to the antigen. There are many in vitro assays for determining cell-mediated immune responses, such as lymphocyte transformation, macrophage migration inhibition, and cytotoxicity tests. These tests require aseptic conditions and long duration of cell culture, and require complex The technical operation process, thus limiting its promotion and application. In 1972 Halliday first introduced a new in vitro test for CMI called